Literature DB >> 15735135

CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate.

Matías Chacón1, Enrique Roca, Eduardo Huertas, Fernando Sanchez Loria, Enzo Domenechini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735135     DOI: 10.1200/JCO.2005.03.194

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.

Authors:  Carla Rameri Alexandre Silva de Azevedo; Tadeu Ferreira Paiva; Benedito Mauro Rossi; Gustavo Cardoso Guimarães; Maria Dirlei Ferreira de Souza Begnami; Thiago Bueno Oliveira; Milton José Barros E Silva; Marcello Ferretti Fanelli; Celso Abdon Lopes de Mello
Journal:  Int J Clin Oncol       Date:  2010-10-05       Impact factor: 3.402

2.  Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate.

Authors:  Seiji Suzuki; Koji Sasajima; Masayuki Miyamoto; Hidehiro Watanabe; Tadashi Yokoyama; Hiroshi Maruyama; Takeshi Matsutani; Aimin Liu; Masaru Hosone; Shotaro Maeda; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

3.  Effective Downsizing of a Gastroesophageal GIST Using Neoadjuvant Imatinib Mesylate: a Case Report.

Authors:  Syed Asif; Nikhil Gupta; Gurudutt Gupta; Anurag Mehta; Shivendra Singh
Journal:  J Gastrointest Cancer       Date:  2017-06

4.  Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors.

Authors:  Silke Cameron; Theodoros Savvoukidis; Thomas Armbrust; Florian Haller; Julia Kitz; László Füzesi; Giuliano Ramadori
Journal:  Med Oncol       Date:  2009-03-18       Impact factor: 3.064

Review 5.  Get the GIST? An overview of gastrointestinal stromal tumours.

Authors:  G A Watson; D Kelly; M Melland-Smith; J Gleeson; G McEntee; C M Kelly; J A McCaffrey
Journal:  Ir J Med Sci       Date:  2016-02-01       Impact factor: 1.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.